Jul 27, 2026 06:09AM
Jul 24, 2026 01:40PM
Jul 17, 2026 04:09PM
Jun 17, 2026 06:49AM
Jun 16, 2026 08:02AM
Jun 1, 2026 08:47AM
May 26, 2026 07:03AM Outlook Therapeutics wins FDA appeal for eye drug application
May 18, 2026 06:08AM
May 13, 2026 04:43PM
Apr 7, 2026 08:56AM
Mar 16, 2026 08:06AM
Mar 5, 2026 04:16PM
Feb 11, 2026 08:45AM
Jan 5, 2026 06:41AM Outlook Therapeutics Inc. (OTLK) PT Lowered to $0.50 at H.C. Wainwright
Jan 5, 2026 06:08AM
Jan 5, 2026 05:33AM
Jan 2, 2026 09:17AM
Jan 2, 2026 07:02AM
Dec 31, 2025 04:15PM
Dec 19, 2025 08:05AM
Nov 13, 2025 08:31AM Outlook Therapeutics gets FDA acceptance for wet AMD drug application
Nov 3, 2025 08:35AM
Sep 30, 2025 06:54AM
Sep 29, 2025 04:03PM
Sep 29, 2025 08:45AM
Sep 2, 2025 08:35AM
Aug 29, 2025 06:51AM
Aug 28, 2025 12:43PM Guggenheim Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral
Aug 28, 2025 06:53AM
Aug 14, 2025 04:15PM
Jul 22, 2025 08:40AM
Jul 1, 2025 08:06AM
Jun 13, 2025 06:53AM
Jun 10, 2025 08:06AM
Jun 6, 2025 05:23AM Outlook Therapeutics Incs. (OTLK) PT Lowered to $21 at Ascendiant Capital
Jun 2, 2025 07:03AM
May 23, 2025 06:39AM
May 22, 2025 04:05PM
Apr 9, 2025 07:21AM
Apr 8, 2025 05:02PM
Apr 8, 2025 08:45AM
Feb 28, 2025 08:05AM Outlook Therapeutics (OTLK) Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Feb 18, 2025 06:44AM
Jan 31, 2025 08:05AM
Jan 23, 2025 09:05AM
Jan 16, 2025 06:01AM
Dec 27, 2024 08:07AM
Dec 13, 2024 04:33PM
Dec 4, 2024 08:06AM Outlook Therapeutics (OTLK) Announces NICE Recommendation of LYTENAVA for the Treatment of Wet AMD
Dec 3, 2024 04:31PM

435,520 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All